Genstar Capital-backed Flourish Research completed the acquisition of Diablo Clinical Research.

Genstar Capital-backed Flourish Research, a clinical trial company focused on conducting research in three core therapeutic areas, completed the acquisition of Diablo Clinical Research, a clinical trials company for pharmaceuticals and medical devices. Financial terms were not disclosed. "The missions of Flourish and Diablo are identical–advancing clinical research to bring life-enhancing therapies to market safely and effectively. By joining Flourish, our experienced principal investigators, management team, and staff can combine expertise that will be of great value to our sponsors and participants," Emily Galdes, Diablo Clinical Research Chief Operating Officer.